Ingo Borggraefe

Ingo Borggraefe

Auto-generated profile, based on publicly available information

Ingo Borggraefe

Abteilung Pädiatrische Neurologie, Entwicklungsneurologie und Sozialpädiatrie, Kinderklinik und Kinderpoliklinik im Dr. von Haunerschen Kinderspital Integriertes Sozialpädiatrisches Zentrum, Interdisziplinäres Epilepsiezentrum, LMU Klinikum, München, Deutschland

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2010 in European Journal of Paediatric Neurology
Verified
Journal Article
Closed access
IBIngo Borggraefe
Ingo Borggraefe
JSJan Simon Schaefer
Jan Simon Schaefer
MKMirjam Klaiber
Mirjam Klaiber
EDEdward Dabrowski
Edward Dabrowski
CACorinne Ammann-Reiffer
Corinne Ammann-Reiffer
AMAndreas Meyer-Heim
Andreas Meyer-Heim

1 January 2020 in European Journal of Medical Genetics
Verified
Journal Article
Closed access
MKM. Kuersten
M. Kuersten
MTM. Tacke
M. Tacke
LGL. Gerstl
L. Gerstl
HHH. Hoelz
H. Hoelz
CSC.V. Stülpnagel
C.V. Stülpnagel
IBI. Borggraefe
I. Borggraefe

25 January 2008 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
IBIngo Borggraefe
Ingo Borggraefe
AMAndreas Meyer‐Heim
Andreas Meyer‐Heim
AKAnita Kumar
Anita Kumar
JSJan Simon Schaefer
Jan Simon Schaefer
SBSteffen Berweck
Steffen Berweck
FHFlorian Heinen
Florian Heinen

22 July 2024 in Nature Genetics
Verified
Journal Article
Open access
PDF file
ASAxel Schmidt
Axel Schmidt
MDMagdalena Danyel
Magdalena Danyel
KGKathrin Grundmann
Kathrin Grundmann
TBTheresa Brunet
Theresa Brunet
HKHannah Klinkhammer
Hannah Klinkhammer
MWMatias Wagner
Matias Wagner
Individuals with ultrarare disorders pose a structural challenge for healthcare systems since expert clinical knowledge is required to establish diagnoses. In TRANSLATE NAMSE, a 3-year prospective study, we evaluated a novel diagnostic concept based on multidisciplinary expertise in Germany. Here we present the systematic investigation of the phenotypic and molecular genetic data of 1,577 patients who had undergone exome sequencing and were partially analyzed with next-generation phenotyping approaches. Molecular genetic diagnoses were established in 32% of the patients totaling 370 distinct molecular genetic causes, most with prevalence below 1:50,000. During the diagnostic process, 34 novel and 23 candidate genotype–phenotype associations were identified, mainly in individuals with neurodevelopmental disorders. Sequencing data of the subcohort that consented to computer-assisted analysis of their facial images with GestaltMatcher could be prioritized more efficiently compared with approaches based solely on clinical features and molecular scores. Our study demonstrates the synergy of using next-generation sequencing and phenotyping for diagnosing ultrarare diseases in routine healthcare and discovering novel etiologies by multidisciplinary teams.

6 February 2023 in Epilepsia Open
Verified
Journal Article
Open access
FKFabienne Kühne
Fabienne Kühne
LBLena-Luise Becker
Lena-Luise Becker
TBThomas Bast
Thomas Bast
ABAstrid Bertsche
Astrid Bertsche
IBIngo Borggraefe
Ingo Borggraefe
AKAngela M. Kaindl
Angela M. Kaindl
Objective: Cannabidiol (CBD) is approved for treatment of Dravet syndrome (DS), Lennox‐Gastaut syndrome (LGS), and tuberous sclerosis complex (TSC). Several studies suggest antiseizure effects also beyond these three epilepsy syndromes.Methods: In a retrospective multicenter study, we analyzed the efficacy and tolerability of CBD in patients with epilepsy at 16 epilepsy centers.Results: The study cohort comprised 311 patients with epilepsy with a median age of 11.3 (0‐72) years (235 children and adolescents, 76 adults). Therapy with CBD was off‐label in 91.3% of cases due to age, epilepsy subtype, lack of adjunct therapy with clobazam, and/or higher dose applied. CBD titration regimens were slower than recommended, with good tolerability of higher doses particularly in children. Of all patients, 36.9% experienced a reduction in seizure frequency of >50%, independent of their epilepsy subtype or clobazam co‐medication. The median observation period was 15.8 months. About one third of all patients discontinued therapy within the observation period due to adverse effects or lack of efficacy. Adverse effects were reported frequently (46.9%).Significance: Our study highlights that CBD has an antiseizure effect comparable to other antiseizure medications with a positive safety profile independent of the epilepsy subtype. Comedication with clobazam was not associated with a better outcome. Higher doses to achieve seizure frequency reduction were safe, particularly in children. These findings call for further trials for an extended approval of CBD for other epilepsy subtypes and for children <2 years of age.

1 September 2013 in European Journal of Paediatric Neurology
Verified
Journal Article
Closed access
IBIngo Borggraefe
Ingo Borggraefe
Michaela V. BonfertMichaela V. Bonfert
Michaela V. Bonfert
TBThomas Bast
Thomas Bast
BNBernd Axel Neubauer
Bernd Axel Neubauer
KSKlaus Juergen Schotten
Klaus Juergen Schotten
FHFlorian Heinen
Florian Heinen